BioWorld

April 28, 2008

Astellas, CoMentis in $760M Deal for Alzheimer's Treatment

Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today) Read More

FDA OKs Progenics Drug; EMA also Gives It a Nod

Japan Pharmas' Love for U.S. Biotechs Just Heating Up

Observational Trials Have Merits, but Stark Limits also Apparent

Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab

Isis Shares Slip on Need for Mipomersen Data

House Measure Reauthorizes BIO-Backed SBIR Grants

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...